• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Scorpion Biological Services Plans Manhattan, Kansas, Biomanufacturing Campus

Scorpion Biological Services, a subsidiary of Heat Biologics, Inc., is building a new 500,000 square foot biomanufacturing facility in Manhattan, Kansas. The $650 million project is expected to create 500 jobs over the next seven years.

The facility will support the development of vaccines that enable an accelerated response to global biological threats. In addition, the company intends to provide commercial level development, manufacturing, and bioanalytical testing services at every stage for biopharmaceutical products on a fee-for-service basis to the global health care industry.

“We are very excited to break ground on this new facility. There is a strong demand for world-class biomanufacturing, which we expect to continue well into the future. We intend to help fill that demand with our newest facility in Manhattan, Kansas,” David Halverson, president of Heat’s Scorpion subsidiary said.

According to state officials, the combination of a world-class public research university, innovative private sector partners and critical national security led Scorpion to choose Manhattan for its new facility. Adding to this, the skill and strength of the Kansas workforce will support the success of this project with Kansas’ brightest minds and hard workers joining the efforts.

“Kansas is the center of the country, with quick access to either coast, a strong workforce, and a growing economy, so there’s no better state for Scorpion to locate to address potential threats to public health,” Governor Laura Kelly said. “Scorpion’s selection of locating this facility in the state reinforces what many have come to learn, Kansas is open for business.”

Scorpion Biological Services (Scorpion) is a contract research, and contract development and manufacturing organization (CDMO) focused on cell- and gene-based therapies and large molecule biologics. The company provides a broad array of biologic manufacturing, analytical and R&D services to pharmaceutical and biotech companies to advance their discoveries and deliver new therapies to patients from our San Antonio facilities, with a focus on offering services using American equipment, reagents, and materials.

“We are showing again and again that we have what it takes to attract highly innovative and highly-technical businesses to Kansas,” Lieutenant Governor and Commerce Secretary David Toland said. “It’s absolutely critical that we, as a nation, increase our capacity for domestic production of these types of vaccines and we are extremely proud to see this work happening here in Kansas.” Scorpion’s biomanufacturing facility represents a new chapter for the company, and it opens the door to a more prepared, innovative, and resilient future when it comes to how our nation, and the world, will respond to biological threats.

This project came together as a result of partnerships between the Kansas Department of Commerce, Kansas State University, Kansas State University Innovation Partners, the City of Manhattan, the Manhattan Chamber of Commerce, Pottawatomie County, Pottawatomie County Economic Development Corporation, Manhattan Area Technical College, Evergy, CRB and Realty Trust Group.

Exclusive Research